Onconetix, Inc. Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Consideration Transferred
Onconetix, Inc. (ONCO) reported Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Consideration Transferred of $20.00 million for the 3-month period ending 2023-03-31, per its 10-Q filed 2023-05-12.
Discontinued › Notes › Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation
us-gaap:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred · last filed 2023-05-12
- Onconetix, Inc. business combination, provisional information, initial accounting incomplete, adjustment, consideration transferred for the quarter ending 2023-03-31 was $20.00M.
| Period end | Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Consideration Transferred 3 month |
|---|---|
| 2023-03-31 | $20.00M 10-Q · filed 2023-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |
| REVELATION BIOSCIENCES, INC. (REVB) | United States | $0.004B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |